Audrey Jackson, Ph.D. Email & Phone Number

Arlington, Va, Us

New Brunswick, Nj, Us

• Lead the development and execution of strategies to advance J&J global health and health equity priorities with governments and global institutions. Lead the advancement of R&D, access, and social impact goals• Lead cross-functional teams to drive alignment of priorities and strategies across the highly matrixed company. Manage teams to develop J&J positions, engage with government officials, and support the external engagement of senior J&J executives• Lead J&J engagement in U.S. and international trade associations and with civil society organizations• Manage consultants to provide support on policy development and external engagement.

Advise decision-makers in non-profit, government, and business on how to address unmet medical needs in global and domestic populations.• Policy and program management services, including policy development, strategic planning, and workshops and training.• Communications and stakeholder engagement, including writing, editing, conference development, panel moderation, and meeting facilitation.• Research and analysis, including literature review, landscape analysis, qualitative research, interviews, and focus groups.• Business development and proposal writing

Washington, Dc, Us

By engaging with policymakers, patients, and other stakeholders, developed and drove a global health policy agenda on major entrenched and emerging global infectious diseases.• Secured and managed $1 million in annual grant funding, meeting 100% of yearly objectives.• Hired, trained, and directed a team of research and project assistants. Planned and executed congressional staff delegation trips to visit U.S.-funded health programs in Africa and Asia.• Convened national and international experts, patients and policymakers to find innovative solutions to global health challenges including disease control, health policy, research, and product development. Served as expert spokesperson and moderator for panel discussions, media interviews, and podcasts.• Published reports, commentaries, and blogs with recommended actions for U.S. policymakers.

Vienna, Va, Us

Directed an international policy portfolio on drug-resistant infections—a health priority of President Barack Obama and his administration. Advised the Assistant Secretary of Global Affairs by providing briefings, talking points, and presentations. Coordinated across HHS divisions, including the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and Food and Drug Administration (FDA), and liaised with the State Department, Department of Agriculture, and other U.S. departments. Provided input and recommendations to the White House National Security Council staff. Managed and trained staff.• Advanced the U.S. health agenda by creating a briefing document on global drug-resistant infections for President Obama’s participation at the G7 Summit.• Crafted the U.S. position on a World Health Organization (WHO) policy document, the 2015 Global Action Plan on Antimicrobial Resistance. Drafted U.S. position statement delivered by the U.S. representative at the WHO 2015 World Health Assembly in Geneva.• Hosted delegation from the U.K., including a member of Parliament. Organized a series of discussions with high-level U.S. government representatives, set the agenda, and facilitated the event.• As member of a White House-led interagency working group, created a government-wide policy document, the 2015 National Action Plan on Combating Multidrug-Resistant Tuberculosis.• Managed the expansion of the U.S.-European Union Transatlantic Task Force on Antimicrobial Resistance (TATFAR) to add national health departments of Canada and Norway.

Supported the Forum for Collaborative HIV Research in its vision to advance drug, vaccine, and diagnostic development by convening pre-competitive collaborative discussions with top academic researchers, U.S. and European government regulators, and pharmaceutical scientists.• Supported expansion into new disease areas: liver disease and cytomegalovirus infection.• Attended the inaugural Liver Forum meeting and wrote reports outlining current research and elucidating major obstacles in drug and diagnostic development. Reviewed and edited other staff’s reports.

Arlington, Virginia, Us

Developed policy on infectious disease issues, such as antimicrobial resistance, drug R&D, vaccines, diagnostics, emerging diseases, and global health. Oversaw programmatic and grassroots advocacy activities for 10,000 physician members. Managed budgets and supervised staff.• Defined the Society’s positions, met with Congressional and Executive Branch staff, and fostered relationships with other advocacy organizations to build coalitions focused on achieving mutual goals. Advocacy contributed to new FDA regulatory guidance on antibiotic drug development for drug-resistant infections and new legislation that provided regulatory incentives for antibiotic development.• Launched new initiative on diagnostics policy and published journal article on accelerating the development and use of infectious disease diagnostics. Met with senior government officials to promote recommendations.• Created annual career development conference for infectious disease research fellows (co-sponsored by IDSA and the National Institute of Allergy and Infectious Diseases) to support physicians on a research career track and address the workforce shortage of physician-scientists.• Co-authored report on public health challenges during the 2009 H1N1 influenza pandemic; persuaded policymakers to adopt policy changes improving preparedness and response capabilities.

Boston, Ma, Us

Conducted research on how the immune system develops, and how leukemia may result from abnormal function. Co-authored articles published in peer-reviewed journals. Sought-after by other research fellows for scientific, experimental, and career-development advice. Awarded $37K postdoctoral grant.• Applied whole genome sequencing technology to investigate genome-wide regulation by a family of transcription factors and chromatin remodeling factors.* equal contributionsJ. Zhang*, A. F. Jackson*, T. Naito*, M. Dosei, J. Seavitt, F. Liu, E. J. Heller, M. Kashiwagi, T. Yoshida, F. Gounari, H. Petrie and K. Georgopoulos. Harnessing of the Nucleosome Remodeling Deacetylase complex controls lymphocyte development and prevents leukemogenesis. Nature Immunology 13, 86 (Jan, 2012) doi:10.1038/ni.2150P. Gomez-Del Arco, M. Kashiwagi*, A. F. Jackson*, T. Naito*, J. Zhang, F. Liu, B. Kee, F. Radtke, J. M. Redondo and K. Georgopoulos. Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis. Immunity 33, 685 (Nov, 2010).

New Haven, Ct, Us

Collaborated in developing award-winning proposal for the Bill & Melinda Gates Foundation Grand Challenges on how the malaria mosquito uses of its sense of smell to find human hosts. The $9.8M grant funded a five-year international scientific collaboration on identifying new insect repellents. Also conducted independent research on bacteria, and discovered a previously unknown phenomenon, published in a top science journal, Nature. Awarded the prestigious, five-year Howard Hughes Medical Institute Predoctoral Fellowship ($185K).* equal contributionsP. Montero Llopis*, A. F. Jackson*, O. Sliusarenko, I. Surovtsev, J. Heinritz, T. Emonet, and C. Jacobs-Wagner. Spatial organization of the flow of genetic information in bacteria. Nature 466, 77 (July 1, 2010).

Planned and managed consulting engagements with large-scale pharmaceutical and biotechnology companies. Designed and implemented qualitative research with consumers and patients on therapeutics and vaccines. Translated findings into customized stakeholder engagement strategies for R&D and all stages of the product life cycle. Ranked in the top 10% companywide.

Doctor Of Philosophy - Phd, Molecular, Cellular, And Developmental Biology

Master Of Science - Ms, Molecular, Cellular, And Developmental Biology

Ab Magna Cum Laude, Biology